ZBH icon

Zimmer Biomet

109.56 USD
+0.62
0.57%
At close Jan 17, 4:00 PM EST
After hours
109.57
+0.01
0.01%
1 day
0.57%
5 days
4.59%
1 month
1.39%
3 months
4.39%
6 months
-1.34%
Year to date
4.88%
1 year
-10.37%
5 years
-26.66%
10 years
-5.46%
 

About: Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Employees: 18,000

0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

3% less funds holding

Funds holding: 992 [Q2] → 962 (-30) [Q3]

3.94% less ownership

Funds ownership: 93.27% [Q2] → 89.33% (-3.94%) [Q3]

6% less capital invested

Capital invested by funds: $20.8B [Q2] → $19.6B (-$1.21B) [Q3]

16% less first-time investments, than exits

New positions opened: 80 | Existing positions closed: 95

25% less funds holding in top 10

Funds holding in top 10: 8 [Q2] → 6 (-2) [Q3]

26% less repeat investments, than reductions

Existing positions increased: 293 | Existing positions reduced: 394

59% less call options, than puts

Call options by funds: $53.7M | Put options by funds: $131M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$117
7%
upside
Avg. target
$121
11%
upside
High target
$128
17%
upside

5 analyst ratings

positive
40%
neutral
40%
negative
20%
Truist Securities
Richard Newitter
79% 1-year accuracy
33 / 42 met price target
8%upside
$118
Hold
Maintained
18 Dec 2024
JP Morgan
Robbie Marcus
62% 1-year accuracy
13 / 21 met price target
17%upside
$128
Overweight
Upgraded
17 Dec 2024
Barclays
Matt Miksic
67% 1-year accuracy
24 / 36 met price target
8%upside
$118
Underweight
Maintained
12 Dec 2024
RBC Capital
Shagun Singh
46% 1-year accuracy
32 / 69 met price target
14%upside
$125
Outperform
Maintained
4 Nov 2024
Wells Fargo
Larry Biegelsen
63% 1-year accuracy
29 / 46 met price target
7%upside
$117
Equal-Weight
Maintained
31 Oct 2024

Financial journalist opinion

Based on 4 articles about ZBH published over the past 30 days

Neutral
PRNewsWire
4 days ago
Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2024 Financial Results
WARSAW, Ind., Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m.
Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2024 Financial Results
Positive
Zacks Investment Research
6 days ago
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
Positive
Seeking Alpha
2 weeks ago
Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook
Zimmer Biomet Holdings (ZBH) is expanding its product portfolio and improving cash flow, positioning it for long-term profitability and financial health. ZBH is undervalued compared to peers, with significant growth potential driven by innovation, acquisitions, and operational efficiency improvements. The company's focus on high-growth markets and improving profitability metrics indicate a strong future outlook, despite past underperformance.
Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook
Positive
Zacks Investment Research
3 weeks ago
ZBH Stock to Benefit From Global Expansion Despite Macro Issues
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
ZBH Stock to Benefit From Global Expansion Despite Macro Issues
Neutral
PRNewsWire
1 month ago
Zimmer Biomet to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WARSAW, Ind. , Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43rd Annual J.P.
Zimmer Biomet to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Neutral
PRNewsWire
1 month ago
Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2024
WARSAW, Ind. , Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024.
Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2024
Positive
Zacks Investment Research
1 month ago
ZBH Stock Might Rise Following FDA Nod for OsseoFit
Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
ZBH Stock Might Rise Following FDA Nod for OsseoFit
Neutral
PRNewsWire
1 month ago
Zimmer Biomet Receives FDA Clearance for OsseoFit™ Stemless Shoulder System for Total Shoulder Replacement
New Anatomically Shaped Asymmetric Stemless Design for Total Shoulder Replacement WARSAW, Ind., Dec. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the OsseoFit™ Stemless Shoulder System for total shoulder replacement.
Zimmer Biomet Receives FDA Clearance for OsseoFit™ Stemless Shoulder System for Total Shoulder Replacement
Negative
MarketBeat
1 month ago
2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead
Robotic surgery used to be fodder for science fiction movies. Not anymore.
2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead
Positive
Zacks Investment Research
1 month ago
Reasons to Retain ZBH Stock in Your Portfolio for Now
Zimmer Biomet's robust efforts to expand market share and a gradually stabilizing musculoskeletal market appear promising.
Reasons to Retain ZBH Stock in Your Portfolio for Now
Charts implemented using Lightweight Charts™